NCT05206149View on ClinicalTrials.gov

Stimulation Test With Intranasal Glucagon for Corticotroph, Somatotroph and Antidiuretic Axes

PHASE4CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions
Hypopituitarism
Interventions
DRUG

Intranasal glugagon

Intranasal glucagon is administered at the dose of 3 mg. This corresponds to the administration of a single dose of Baqsimi®.

DRUG

Intranasal placebo

Intranasal placebo (represented by isotonic saline solution) is administered.

Trial Locations (1)

10126

AOU Città della Salute e della Scienza, Turin

All Listed Sponsors
lead

A.O.U. Città della Salute e della Scienza

OTHER

NCT05206149 - Stimulation Test With Intranasal Glucagon for Corticotroph, Somatotroph and Antidiuretic Axes | Biotech Hunter | Biotech Hunter